Drugs / GSK1018921
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00929370 | Jul → Oct 2008 | schizophrenia | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00945503 | May → Dec 2008 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00527020 | Aug 2007 → Jul 2008 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1018921 | “GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).” NCT00929370 ↗ |
| Action | Inhibit | “potent and selective inhibitor of the glycine transporter-1 (GlyT-1)” NCT00929370 ↗ |
| Route | Oral | “Single Oral Escalating Doses of GSK1018921” NCT00527020 ↗ |